Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ariad Pharmaceuticals Inc Terminates Late Stage Study Of Cancer Drug-Reuters


Friday, 18 Oct 2013 07:24am EDT 

Reuters reported that Ariad Pharmaceuticals Inc said it would discontinue a late-stage trial of its blood cancer drug, barely two weeks after the U.S. Food and Drug Administration placed a partial hold on enrollment for all trials testing the drug. The Company said it had come to an agreement with the FDA that the trial should be terminated as patients treated with the drug, Iclusig, had developed blood clots in their arteries. 

Company Quote

6.61
0.25 +3.93%
18 Dec 2014